Foreign manufacturers entering the U.S. market must comply with strict Food and Drug Administration (FDA) regulations. One of the most critical requirements for overseas companies is the appointment of a U.S. Agent. This role is mandatory for foreign establishments involved in the manufacturing, processing, packaging, or holding of FDA-regulated products including drugs, medical devices, food, […] The post How to Appoint a U.S. Agent for FDA Compliance: Things You Need to Know appeared first on TechBullion.Foreign manufacturers entering the U.S. market must comply with strict Food and Drug Administration (FDA) regulations. One of the most critical requirements for overseas companies is the appointment of a U.S. Agent. This role is mandatory for foreign establishments involved in the manufacturing, processing, packaging, or holding of FDA-regulated products including drugs, medical devices, food, […] The post How to Appoint a U.S. Agent for FDA Compliance: Things You Need to Know appeared first on TechBullion.

How to Appoint a U.S. Agent for FDA Compliance: Things You Need to Know

2025/11/27 00:29
5 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Foreign manufacturers entering the U.S. market must comply with strict Food and Drug Administration (FDA) regulations. One of the most critical requirements for overseas companies is the appointment of a U.S. Agent. This role is mandatory for foreign establishments involved in the manufacturing, processing, packaging, or holding of FDA-regulated products including drugs, medical devices, food, dietary supplements, cosmetics, and biologics.

To streamline U.S. Agent appointment, regulatory communication, and FDA submission management, foreign companies can refer to a professional service provider here:

How to Appoint U.S. Agent for FDA Compliance: Things You Need to Know

Why the FDA Requires a U.S. Agent

The United States FDA enforces regulations that ensure the safety, quality, and compliance of all imported products. To maintain effective communication with foreign firms, the FDA mandates the appointment of a domestic representative. This ensures that:

  • All regulatory messages reach the foreign establishment promptly
  • FDA inspection notices are formally acknowledged
  • Emergency notifications are handled without delay
  • Submission queries and compliance discussions have a U.S.-based point of contact

Failure to designate a compliant U.S. Agent may result in delayed approvals, import refusals, enforcement actions, or removal of the company from FDA’s establishment registration database.

Responsibilities of a U.S. Agent

The U.S. Agent plays a vital regulatory and communication role. Their core responsibilities include:

  1. Coordination of FDA Communications

The primary function is to receive, interpret, and respond to FDA communications. This includes notices related to establishment registration, product listing, inspection scheduling, and regulatory inquiries.

  1. Support During FDA Inspections

Foreign facilities may be selected for routine or targeted inspections. The U.S. Agent assists by helping coordinate the inspection logistics, acting as a liaison, and ensuring timely responses to FDA requests.

  1. Regulatory Query Management

When the FDA requires clarifications about documentation, processes, safety data, or compliance issues, the U.S. Agent helps relay information between the FDA and the foreign establishment.

  1. Emergency Contact for the FDA

In urgent situations, such as product contamination, adverse events, safety triggers, or recalls, the FDA must be able to reach a domestic representative immediately.

  1. Assistance With Submissions and Updates

U.S. Agents often assist with:

  • Annual establishment registration updates
  • Drug listing or device listing submissions
  • Importer compliance documentation
  • Maintaining accurate regulatory records

While the U.S. Agent does not legally assume responsibility for product compliance, they play a central role in ensuring the FDA receives necessary information on time.

Which Companies Must Appoint a U.S. Agent?

FDA rules require a U.S. Agent for:

  • Drug manufacturers, repackers, or relabelers (per FD&C Act Section 510)
  • Medical device manufacturers registering under 21 CFR Part 807
  • Food facilities under the Food Safety Modernization Act (FSMA)
  • Cosmetic manufacturers entering the U.S. market
  • Dietary supplement and nutraceutical firms
  • Biologic and vaccine facilities
  • API manufacturers and contract development companies

If a company operates multiple foreign facilities, each establishment must appoint a U.S. Agent individually.

Criteria to Consider When Choosing a U.S. Agent

Appointing a U.S. Agent is not a formality—it is a long-term compliance partnership. When selecting a U.S. Agent, companies should evaluate the following:

  1. Regulatory Knowledge

The agent must understand FDA frameworks such as:

  • Drug and device registration rules
  • eCTD submissions
  • Import compliance requirements
  • Safety reporting obligations
  • FSMA rules for food facilities
  1. Responsiveness

The FDA may require rapid replies. A compliant U.S. Agent must be available to respond promptly, especially during emergencies.

  1. Experience in Handling Inspections

Agents with experience in FDA inspections, Form 483 responses, and regulatory communication help minimize compliance risks.

  1. Confidentiality and Data Security

Handling regulatory filings requires secure data practices and confidentiality agreements to protect sensitive information.

  1. Ability to Support Global Regulatory Strategy

Many professional agents offer additional services:

  • DUNS number support
  • Labeling compliance
  • Importer of Record guidance
  • Submission publishing
  • Regulatory consulting

Such capabilities add value during the entire lifecycle of U.S. market entry.

Steps to Appoint a U.S. Agent

Step 1: Select an Authorized U.S.-Based Individual or Firm

The foreign company must first identify a suitable representative within the United States.

Step 2: Provide Establishment Information

Details such as establishment name, address, DUNS number, product categories, and regulatory activities must be shared.

Step 3: Add the U.S. Agent During FDA Registration

During FDA Facility Registration (for drugs, devices, food, or cosmetics), the foreign establishment lists the appointed U.S. Agent.

Step 4: Agent Confirms Appointment

The U.S. Agent must confirm acceptance through FDA systems such as:

  • FDA Unified Registration and Listing System (FURLS)
  • Device Registration and Listing Module
  • Food Facility Registration Portal

Step 5: Maintain Communication and Annual Updates

FDA registrations must be renewed annually. The U.S. Agent must continue to represent the company and respond to any FDA notices throughout the year.

Consequences of Not Appointing a U.S. Agent

Non-compliance with the U.S. Agent requirement can result in:

  • Foreign establishment registration rejection
  • Import refusal of shipments
  • Delay in marketing authorization
  • Removal from FDA active registration database
  • FDA inability to communicate, triggering administrative holds

Maintaining a reliable U.S. Agent is therefore essential for uninterrupted business operations.

Why Professional U.S. Agent Services Are Recommended

Appointing an experienced regulatory partner helps foreign companies:

  • Avoid registration errors
  • Navigate FDA correspondence professionally
  • Reduce inspection risks
  • Maintain continuous compliance
  • Manage document submissions and updates
  • Ensure timely regulatory communication

Companies entering the U.S. for the first time particularly benefit from structured support and technical guidance.

For complete U.S. Agent support, appointment assistance, regulatory communication management, and FDA compliance solutions, refer here:

How to Appoint U.S. Agent for FDA Compliance: Things You Need to Know

Comments
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Shocking OpenVPP Partnership Claim Draws Urgent Scrutiny

Shocking OpenVPP Partnership Claim Draws Urgent Scrutiny

The post Shocking OpenVPP Partnership Claim Draws Urgent Scrutiny appeared on BitcoinEthereumNews.com. The cryptocurrency world is buzzing with a recent controversy surrounding a bold OpenVPP partnership claim. This week, OpenVPP (OVPP) announced what it presented as a significant collaboration with the U.S. government in the innovative field of energy tokenization. However, this claim quickly drew the sharp eye of on-chain analyst ZachXBT, who highlighted a swift and official rebuttal that has sent ripples through the digital asset community. What Sparked the OpenVPP Partnership Claim Controversy? The core of the issue revolves around OpenVPP’s assertion of a U.S. government partnership. This kind of collaboration would typically be a monumental endorsement for any private cryptocurrency project, especially given the current regulatory climate. Such a partnership could signify a new era of mainstream adoption and legitimacy for energy tokenization initiatives. OpenVPP initially claimed cooperation with the U.S. government. This alleged partnership was said to be in the domain of energy tokenization. The announcement generated considerable interest and discussion online. ZachXBT, known for his diligent on-chain investigations, was quick to flag the development. He brought attention to the fact that U.S. Securities and Exchange Commission (SEC) Commissioner Hester Peirce had directly addressed the OpenVPP partnership claim. Her response, delivered within hours, was unequivocal and starkly contradicted OpenVPP’s narrative. How Did Regulatory Authorities Respond to the OpenVPP Partnership Claim? Commissioner Hester Peirce’s statement was a crucial turning point in this unfolding story. She clearly stated that the SEC, as an agency, does not engage in partnerships with private cryptocurrency projects. This response effectively dismantled the credibility of OpenVPP’s initial announcement regarding their supposed government collaboration. Peirce’s swift clarification underscores a fundamental principle of regulatory bodies: maintaining impartiality and avoiding endorsements of private entities. Her statement serves as a vital reminder to the crypto community about the official stance of government agencies concerning private ventures. Moreover, ZachXBT’s analysis…
Share
BitcoinEthereumNews2025/09/18 02:13
A Netflix ‘KPop Demon Hunters’ Short Film Has Been Rated For Release

A Netflix ‘KPop Demon Hunters’ Short Film Has Been Rated For Release

The post A Netflix ‘KPop Demon Hunters’ Short Film Has Been Rated For Release appeared on BitcoinEthereumNews.com. KPop Demon Hunters Netflix Everyone has wondered what may be the next step for KPop Demon Hunters as an IP, given its record-breaking success on Netflix. Now, the answer may be something exactly no one predicted. According to a new filing with the MPA, something called Debut: A KPop Demon Hunters Story has been rated PG by the ratings body. It’s listed alongside some other films, and this is obviously something that has not been publicly announced. A short film could be well, very short, a few minutes, and likely no more than ten. Even that might be pushing it. Using say, Pixar shorts as a reference, most are between 4 and 8 minutes. The original movie is an hour and 36 minutes. The “Debut” in the title indicates some sort of flashback, perhaps to when HUNTR/X first arrived on the scene before they blew up. Previously, director Maggie Kang has commented about how there were more backstory components that were supposed to be in the film that were cut, but hinted those could be explored in a sequel. But perhaps some may be put into a short here. I very much doubt those scenes were fully produced and simply cut, but perhaps they were finished up for this short film here. When would Debut: KPop Demon Hunters theoretically arrive? I’m not sure the other films on the list are much help. Dead of Winter is out in less than two weeks. Mother Mary does not have a release date. Ne Zha 2 came out earlier this year. I’ve only seen news stories saying The Perfect Gamble was supposed to come out in Q1 2025, but I’ve seen no evidence that it actually has. KPop Demon Hunters Netflix It could be sooner rather than later as Netflix looks to capitalize…
Share
BitcoinEthereumNews2025/09/18 02:23
Bitcoin Cash: price +7% at $647, breakout and key levels (09/18/2025)

Bitcoin Cash: price +7% at $647, breakout and key levels (09/18/2025)

Bitcoin Cash gains 7% and reaches $647, hitting highs not seen since last April: the movement fits into a risk-on climate.
Share
The Cryptonomist2025/09/18 21:47